Compare ADMA Biologics Inc (ADMA) vs Monster Beverage Corp (MNST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Monster Beverage Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Monster Beverage Corp trades at $95.68 (market cap $94.79B). The key difference: Monster Beverage Corp is far larger — about 44.5× ADMA Biologics Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MNST | |
|---|---|---|
Market Cap | $2.13B | $94.79B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $97.64 |
52-Week Low | $7.60 | $58.65 |
Enterprise Value | $2.20B | $93.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Monster Beverage (MNST) trades at $96.92, down 0.7% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growing from $6.3B in 2022 to $8.3B in 2025 and net income reaching $1.91B. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.58 exceeding the $0.527 forecast. Analyst sentiment remains positive with 53% buy ratings, though valuation metrics appear elevated with a P/E of 47.04.
MNST presents growth opportunities through international expansion and product innovation, with overseas sales reaching 45% of revenue. However, the stock faces risks from premium valuation levels and competitive pressures in the energy drink market. The consensus price target of $91.67 suggests potential downside from current levels, while technical indicators show the stock trading near resistance at $98-$100.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
